Skip to main content

AI-enabled RNA nanotechnology DElivery SysTem for INformATION transfer into cells.

Objective

By combining the interdisciplinary fields of AI/machine learning with RNA nanotechnology, biochemistry and advanced imaging methods, DESTINATION aims to create a first-generation RNA-based delivery platform (RNano) for effective delivery of information such as mRNA into cells in vivo. mRNA translate the information encoded in a cell’s DNA into the proteins that are essential for diverse cell function and can be deficient in disease. Administering mRNA into a cell could enable diverse novel functions such as production of its own medicine by replacing the faulty mRNA or engineering cells to fight diseases from genetic disorders and cancer to infectious diseases. However, the ability to deliver mRNA to specific cells in a targeted organ remains an unmet challenge that limits its clinical and commercial potential. Addressing this challenge requires a novel, biocompatible and scalable system capable of (1) protecting the mRNA from degradation in blood; (2) evading the immune response; (3) and providing high selectivity for targeted cells. DESTINATION will generate an intelligent library of (a) programmable RNano scaffolds for attachment of packaged mRNA and (b) RNA aptamers for laser-specific internalization of RNanos into cells. Promising candidates will be tested in vitro, with lead candidates progressed to novel animal models. Ultra high-resolution imaging will allow for the evaluation of the technology, with an iterative R&D approach aimed at demonstrating 3breakthrough preclinical proof-of-concepts incl. in the attractive field of CAR-T cancer immune-therapies. DESTINATION comprises a multi-disciplinary consortium of top academics and 3 R&D-performing SMEs acting as commercialization agents to increase DESTINATION’s impact by developing a translation strategy and communication plan focused on providing early engagement with investors, regulators, potential manufacturing and industry partners. Together, DESTINATION will strengthen EU's position in the emerging fields of RNA technology.

Field of science

  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /natural sciences/biological sciences/genetics and heredity/rna
  • /medical and health sciences/clinical medicine/cancer
  • /engineering and technology/nanotechnology

Call for proposal

H2020-FETOPEN-2018-2019-2020-01
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

SIXFOLD BIOSCIENCE LTD
Address
The Imperial College White City Inc Innovation Hub
W12 0BZ London
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 886 250

Participants (6)

EXPLORA SRL
Italy
EU contribution
€ 492 473,75
Address
Via Giacomo Peroni 386
00131 Roma
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Spain
EU contribution
€ 509 183,75
Address
Avenida De Pio Xii 55
31008 Pamplona
Activity type
Research Organisations
UNIVERSITY OF NEWCASTLE UPON TYNE
United Kingdom
EU contribution
€ 572 336,25
Address
Kings Gate
NE1 7RU Newcastle Upon Tyne
Activity type
Higher or Secondary Education Establishments
TECHNISCHE UNIVERSITEIT EINDHOVEN
Netherlands
EU contribution
€ 306 750
Address
Groene Loper 3
5612 AE Eindhoven
Activity type
Higher or Secondary Education Establishments
FUTURESYNTHESIS SP ZOO
Poland
EU contribution
€ 222 125
Address
Rubiez, Nr 46, Lok. B
61612 Poznan
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Germany
EU contribution
€ 392 770
Address
Regina Pacis Weg 3
53113 Bonn
Activity type
Higher or Secondary Education Establishments